Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GD2 expression in breast cancer.
Orsi G, Barbolini M, Ficarra G, Tazzioli G, Manni P, Petrachi T, Mastrolia I, Orvieto E, Spano C, Prapa M, Kaleci S, D'Amico R, Guarneri V, Dieci MV, Cascinu S, Conte P, Piacentini F, Dominici M. Orsi G, et al. Among authors: barbolini m. Oncotarget. 2017 May 9;8(19):31592-31600. doi: 10.18632/oncotarget.16363. Oncotarget. 2017. PMID: 28415563 Free PMC article.
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus.
Omarini C, Filieri ME, Bettelli S, Manfredini S, Kaleci S, Caprera C, Nasso C, Barbolini M, Guaitoli G, Moscetti L, Maiorana A, Conte PF, Cascinu S, Piacentini F. Omarini C, et al. Among authors: barbolini m. Biomed Res Int. 2018 Jul 24;2018:3756981. doi: 10.1155/2018/3756981. eCollection 2018. Biomed Res Int. 2018. PMID: 30140695 Free PMC article.
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials.
Omarini C, Piacentini F, Sperduti I, Barbolini M, Isca C, Toss A, Cortesi L, Barbieri E, Dominici M, Moscetti L. Omarini C, et al. Among authors: barbolini m. BMC Cancer. 2020 May 13;20(1):418. doi: 10.1186/s12885-020-06933-y. BMC Cancer. 2020. PMID: 32404154 Free PMC article.
Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib.
Omarini C, Molinaro E, Barbolini M, Dominici M, Piacentini F. Omarini C, et al. Among authors: barbolini m. Breast. 2020 Aug;52:132-133. doi: 10.1016/j.breast.2020.05.011. Epub 2020 Jun 2. Breast. 2020. PMID: 32512359 Free PMC article. No abstract available.
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature.
Isca C, Piacentini F, Mastrolia I, Masciale V, Caggia F, Toss A, Piombino C, Moscetti L, Barbolini M, Maur M, Dominici M, Omarini C. Isca C, et al. Among authors: barbolini m. Cancers (Basel). 2021 Sep 29;13(19):4894. doi: 10.3390/cancers13194894. Cancers (Basel). 2021. PMID: 34638377 Free PMC article.
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy.
Toss A, Venturelli M, Civallero M, Piombino C, Domati F, Ficarra G, Combi F, Cabitza E, Caggia F, Barbieri E, Barbolini M, Moscetti L, Omarini C, Piacentini F, Tazzioli G, Dominici M, Cortesi L. Toss A, et al. Among authors: barbolini m. Front Oncol. 2022 Dec 1;12:1016295. doi: 10.3389/fonc.2022.1016295. eCollection 2022. Front Oncol. 2022. PMID: 36531080 Free PMC article.
30 results